Stevanato Group S.p.A. research snapshot
STVN AI stock analysis reads Stevanato Group as a specialized pharmaceutical glass packaging and drug delivery systems company with a strong market position in insulin cartridges and EZ-fill sterile syringes. At the July 12, 2026 cutoff, the latest verified close was $19.28, market capitalization was about $5.26 billion, and the central question is whether capacity expansion, GLP-1 drug demand, and EZ-fill adoption can sustain revenue growth and margin improvement against a backdrop of heavy capital spending and emerging competition. This is informational research and not investment advice.
Current price
$19.28
Market cap
$5.26 billion
AI score
62 / 100
Rating
Good business at a fair price with execution risk
Trend status
Recovering from lows, below key moving averages
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Stevanato makes glass vials, syringes, cartridges, ampoules, and drug delivery systems for pharma and biotech customers who face high switching costs once packaging is qualified for a drug. | High |
| Moat | Moat comes from regulatory switching costs, global manufacturing scale, proprietary EZ-fill sterile platform, glass forming technology, and long-term customer relationships with top pharma companies. | Medium-high |
| Management | Family-led by the Stevanato family with deep industry knowledge. Capital allocation leans toward capacity investment and US expansion. The key question is whether heavy capex translates to proportionate revenue and FCF growth. | Medium |
| Financial trend | TTM revenue of about $1.2 billion grew at a mid-teens pace. Net income was about $141 million. Free cash flow was negative due to elevated capex for US and global capacity expansion. | Medium-high |
| Valuation | The stock traded near 33x TTM earnings and 19x forward earnings. Enterprise value was about 4x revenue and 17x EBITDA. Margin of safety depends on growth delivery and FCF improvement. | Medium |
| Technical trend | STVN was recovering from a $12.89 low toward the $19.28 level, but remained below its 50-day and 200-day moving averages based on available public technical data near the cutoff. | Medium |
| Risk level | Key risks are customer concentration, pharma end-market cyclicality, raw material cost volatility, US facility execution, negative FCF persistence, currency exposure, and competition from established players. | Medium-high |
| AI confidence | Medium-high confidence for business model understanding, filing-backed financial data, and major risk categories. Lower confidence for near-term price direction and competitive market share evolution. | Medium-high |
| Investment certainty | Medium-low certainty. The business has durable demand drivers, but the stock price embeds growth expectations that require successful capex execution and sustained pharma end-market demand. | Medium-low |
STVN AI stock forecast
The STVN AI stock forecast uses scenario ranges around the $19.28 cutoff price. It does not claim that AI can predict a specific future price. The bullish case assumes GLP-1 drug demand accelerates, the US facility ramps successfully, and margins expand. The base case assumes steady pharma packaging demand with moderate growth. The bearish case assumes execution setbacks, competition, or a pharma spending slowdown.
$26 to $33
More likely if Stevanato sustains 15-20% revenue growth from EZ-fill adoption and GLP-1 drug demand, the Fishers US plant operates near capacity, margins expand, and the market re-rates the stock toward 25-28x forward earnings.
$16 to $22
More likely if revenue grows at a high-single-digit to low-teens pace, capex remains elevated, FCF stays near breakeven, and the stock trades in a 18-22x forward PE range.
$10 to $14
More likely if US facility ramp-up faces delays, GLP-1 demand disappoints, pharma customers destock, negative FCF persists, or competitive pressure from Schott, Gerresheimer, or West Pharma intensifies.
STVN AI technical analysis
STVN AI technical analysis starts from the $19.28 close available near the July 12 cutoff. Public technical data was limited compared to larger-cap stocks. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $19.28 | Latest available close used for this page as of the July 12, 2026 data cutoff. |
| Near support | $17.00 to $17.50 | An intermediate support zone that held in prior trading sessions near the cutoff. |
| Key support | $12.89 | The 52-week low area. A break below this level would signal a significant trend deterioration. |
| Near resistance | $22.00 to $23.00 | An overhead resistance zone from prior consolidation. A break above this could signal trend improvement. |
| Key resistance | $28.00 | The 52-week high. A move above this level would mark a new uptrend and attract momentum interest. |
| Moving averages | Below 50-day and 200-day | Based on available public technical data, STVN traded below both key moving averages near the cutoff, indicating a cautious near-term technical posture. |
| Momentum | Recovering from oversold | The stock had rallied about 50% from the $12.89 low, suggesting short-term momentum improvement but possible near-term exhaustion. |
| Volume | Below average | Average daily volume was around 460,000 shares, with below-average participation in the recovery rally. |
| Volatility | Elevated | With a beta of 0.78 and a wide 52-week range from $12.89 to $28.00, position sizing should account for above-normal single-stock volatility. |
| Invalidation | Close below $17.00 or above $28.00 | A close below $17.00 weakens the recovery setup. A close above $28.00 confirms a new uptrend. |
STVN AI trading strategy
The STVN AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.
Look for STVN to reclaim its 50-day moving average and break above the $22 to $23 resistance zone with improving volume before treating the recovery as a confirmed uptrend.
A failed breakout or daily close back below $17.00 should reduce confidence in the recovery setup.
If STVN pulls back toward $17.00 to $17.50 without a broken thesis, monitor quarterly results, US facility updates, and EZ-fill customer wins for fundamental confirmation.
Do not average down solely because Stevanato has a strong niche. Define maximum position loss and review capex and FCF trends first.
Track quarterly revenue growth, EZ-fill and GLP-1-related order trends, US plant utilization, FCF trajectory, gross margin progression, and backlog from the Engineering division.
Lower the rating if revenue growth decelerates below 8% or if negative FCF persists beyond FY2026 without a clear improvement path.
Investment research summary
Stevanato makes specialized glass containers and drug delivery systems for injectable pharmaceuticals, with customers locked in by regulatory qualification and quality validation processes.
The moat is built on regulatory switching costs, global manufacturing footprint, proprietary EZ-fill ready-to-use platform, glass forming machinery know-how, and decades-long customer relationships with top pharma companies.
The thesis can fail if US capacity expansion underperforms, GLP-1 drug demand plateaus, pharma customers destock, competition from Schott or West Pharma intensifies, or heavy capex never translates to FCF generation.
The Stevanato family has operated the business for three generations with good industry knowledge. Capital allocation is heavily tilted toward growth capex. Monitoring items include FCF conversion, project execution timelines, and succession depth.
Stevanato sits at the intersection of injectable drug growth, GLP-1 expansion, biologics demand, and the trend toward ready-to-use containment solutions. The secular trend is strong, but the industry is cyclical with pharma end-market spending.
At roughly 33x TTM earnings and 19x forward earnings, the stock priced in growth but left limited room for execution missteps. A margin of safety requires either durable mid-teens growth or a lower entry price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| STVN price | $19.28 close near July 10, 2026 | Yahoo Finance quote snapshot | July 12, 2026 |
| Market capitalization | $5.26 billion, verified as $19.28 x 273,000,000 shares | financial_rigor.py market cap verification and Yahoo Finance | July 12, 2026 |
| TTM revenue | About $1.2 billion | Yahoo Finance and company filings | July 12, 2026 |
| TTM net income | About $141.35 million | Yahoo Finance and company filings | July 12, 2026 |
| EPS (TTM) | $0.58 | Yahoo Finance | July 12, 2026 |
| Cash and equivalents | $112.28 million (most recent quarter) | Yahoo Finance | July 12, 2026 |
| Total debt/equity | 29.43% | Yahoo Finance | July 12, 2026 |
| Enterprise value | About $5.57 billion | Yahoo Finance | July 12, 2026 |
| TTM PE ratio | 33.24x | financial_rigor.py valuation verification and Yahoo Finance | July 12, 2026 |
| Forward PE ratio | About 19.46x | Yahoo Finance | July 12, 2026 |
| Dividend yield | 0.32% ($0.06 annual) | Yahoo Finance | July 12, 2026 |
| 52-week range | $12.89 to $28.00 | Yahoo Finance | July 12, 2026 |
This STVN AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
